Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.31 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314912 | 0.88 | KMT2A (0.44) | MEN1KMT2APKMPOLBL3MBTL1 | |
| SCHEMBL20314873 | 0.88 | JAK3 (0.41) | JAK3OPRK1TEAD1 | |
| SCHEMBL23544836 | 0.88 | JAK3 (0.41) | JAK3OPRK1TEAD1 | |
| SCHEMBL20314864 | 0.85 | JAK3 (0.34) | JAK3MEN1KMT2APKMOPRK1 | |
| SCHEMBL25839519 | 0.85 | JAK3 (0.34) | JAK3MEN1KMT2APKMOPRK1 | |
| SCHEMBL20314921 | 0.84 | TEAD1 (0.34) | JAK3MEN1KMT2AOPRK1TEAD1 | |
| SCHEMBL21554954 | 0.83 | PIK3CD (0.39) | MEN1KMT2APKMOPRK1POLB | |
| SCHEMBL20314896 | 0.82 | JAK3 (0.33) | JAK3OPRK1TEAD1TEAD3 | |
| SCHEMBL20314946 | 0.82 | TEAD1 (0.33) | JAK3OPRK1TEAD1 | |
| SCHEMBL23545019 | 0.81 | JAK3 (0.36) | JAK3OPRK1TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885MEN1 4006/4885KMT2A 2231/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885MEN1 4006/4885KMT2A 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.